Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Relief Therapeutics Hldg Ag (RLFTF)

Relief Therapeutics Hldg Ag (RLFTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

/PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying,...

RLFTF : 1.3900 (-0.71%)
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

/CNW/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying,...

RLFTF : 1.3900 (-0.71%)
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

/PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx...

RLFTF : 1.3900 (-0.71%)
NRXP : 2.10 (+1.94%)
RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION

/PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (OTCQB: RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx"), today...

RLFTF : 1.3900 (-0.71%)
RLFTY : 1.4006 (-2.06%)
NRXP : 2.10 (+1.94%)
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F

GENEVA, SWITZERLAND / ACCESSWIRE / July 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief ") announced today that the U.S. Securities and Exchange Commission (" SEC ") has...

RLFTY : 1.4006 (-2.06%)
RLFTF : 1.3900 (-0.71%)
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)

GENEVA, SWITZERLAND / ACCESSWIRE / July 18, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), today announced that its collaboration partner, ACER Therapeutics, Inc. ("Acer"),...

RLFTF : 1.3900 (-0.71%)
RLFTY : 1.4006 (-2.06%)
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

Experienced Leader in Commercial and Medical Affairs, With a Focus on Gene Therapy, to Spearhead Relief's New Strategic Foray Into Genetic Medicine

RLFTF : 1.3900 (-0.71%)
RLFTY : 1.4006 (-2.06%)
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU

Company acquires an additional therapeutic product for the management of patients with PKU for worldwide markets, with the exception of the United Kingdom, thereby complementing and enhancing its existing...

RLFTF : 1.3900 (-0.71%)
RLFTY : 1.4006 (-2.06%)
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 4 to its Registration Statement...

RLFTF : 1.3900 (-0.71%)
RLFTY : 1.4006 (-2.06%)
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk

GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...

RLFTY : 1.4006 (-2.06%)
RLFTF : 1.3900 (-0.71%)
NRXP : 2.10 (+1.94%)

Barchart Exclusives

2 Small-Cap Stocks With 40% to 60% Upside
Wall Street believes these two growth stocks will soar, driven by the demand for their products. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar